{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:48:44Z","timestamp":1791953324936,"version":"4.3.4"},"reference-count":222,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Autoimmune bullous diseases (AIBDs) are a group of severe disorders characterized by autoantibodies that attack structural proteins within the skin\/mucosa, leading to blister and bullae formation. Pemphigus vulgaris (PV) and bullous pemphigoid (BP) are among the most prevalent representative AIBDs. Traditional treatments involving corticosteroids and immunosuppressive agents are often associated with substantial adverse effects and a high rate of relapse. In recent years, the therapeutic landscape has evolved toward precision targeted therapies, encompassing biological agents, small-molecule drugs, and chimeric autoantibody receptor T cells. These novel interventions act on specific pathogenic targets, offering the potential to improve both efficacy and safety. This narrative review aims to summarize the latest progress in targeted therapies for PV and BP, compare the mechanisms of action, efficacy, and safety profiles of various treatments, and highlight current challenges and future research directions. In addition, therapeutic considerations for patients with concomitant psoriasis are discussed, given the increasing recognition of this comorbidity in clinical practice and the growing number of case reports describing the use of targeted agents in this specific population. Ultimately, the insights presented herein are intended to optimize clinical management strategies and guide future drug development.<\/jats:p>","DOI":"10.3390\/ijms27198779","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:19:37Z","timestamp":1790777977000},"page":"8779","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Research Progress on Targeted Therapies for Pemphigus Vulgaris and Bullous Pemphigoid: Mechanisms, Opportunities and Challenges"],"prefix":"10.3390","volume":"27","author":[{"given":"Wang-Fei","family":"Mo","sequence":"first","affiliation":[{"name":"Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China"},{"name":"Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2526-4331","authenticated-orcid":false,"given":"Ya-Gang","family":"Zuo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"102852","DOI":"10.1016\/j.autrev.2021.102852","article-title":"MicroRNAs in pemphigus and pemphigoid diseases","volume":"20","author":"Papara","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Papara, C., Karsten, C.M., Ujiie, H., Schmidt, E., Schmidt-Jim\u00e9nez, L.F., Baican, A., Freire, P.C., Izumi, K., Bieber, K., and Peipp, M. (2022). The relevance of complement in pemphigoid diseases: A critical appraisal. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.973702"},{"key":"ref_3","first-page":"1188","article-title":"Pemphigus and pemphigoids: Clinical presentation, diagnosis and therapy","volume":"21","author":"Didona","year":"2023","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jid.2025.05.018","article-title":"The Multikinase Inhibitor Midostaurin Mitigates Loss of Intercellular Adhesion and Skin Blistering in Pemphigus Vulgaris","volume":"146","author":"Hiermaier","year":"2026","journal-title":"J. Investig. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Emtenani, S., Hertl, M., Schmidt, E., and Hudemann, C. (2023). Mouse models of pemphigus: Valuable tools to investigate pathomechanisms and novel therapeutic interventions. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1169947"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41572-025-00595-5","article-title":"Bullous pemphigoid","volume":"11","author":"Akbarialiabad","year":"2025","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.jaad.2020.11.075","article-title":"Intraepithelial autoimmune blistering dermatoses: Clinical features and diagnosis","volume":"84","author":"Montagnon","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12016-024-08980-w","article-title":"A Global View of Pemphigus: Geographical Variations","volume":"66","author":"Rodrigues","year":"2024","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/bjd.15930","article-title":"British Association of Dermatologists\u2019 guidelines for the management of pemphigus vulgaris 2017","volume":"177","author":"Harman","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Rosi-Schumacher, M., Baker, J., Waris, J., Seiffert-Sinha, K., and Sinha, A.A. (2023). Worldwide epidemiologic factors in pemphigus vulgaris and bullous pemphigoid. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1159351"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Baroukhian, J., Seiffert-Sinha, K., and Sinha, A.A. (2024). A comprehensive, population level evaluation of previously reported drug triggers of pemphigus highlights immunomodulatory capacity as a common characteristic. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1508129"},{"key":"ref_12","first-page":"1613","article-title":"Comorbid diseases associated with pemphigus: A case-control study","volume":"19","author":"Bardazzi","year":"2021","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Drenovska, K., Ivanova, M., Vassileva, S., Shahid, M.A., and Naumova, E. (2022). Association of specific HLA alleles and haplotypes with pemphigus vulgaris in the Bulgarian population. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.901386"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Jukic, I.L., Mokos, M., and Marinovic, B. (2023). HLA class II antigens in Croatian patients with pemphigus vulgaris and their correlation with anti-desmoglein antibodies. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1200992"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jaad.2020.05.161","article-title":"Subepithelial autoimmune bullous dermatoses disease activity assessment and therapy","volume":"85","author":"Montagnon","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/jdv.17107","article-title":"Incidence of pemphigoid diseases in Northern Germany in 2016\u2014First data from the Schleswig-Holstein Registry of Autoimmune Bullous Diseases","volume":"35","author":"Weidinger","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/bjd.20743","article-title":"The global incidence of bullous pemphigoid: A systematic review and meta-analysis","volume":"186","author":"Persson","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/bjd.19022","article-title":"Incidence, prevalence and mortality of bullous pemphigoid in England 1998-2017: A population-based cohort study","volume":"184","author":"Persson","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Yang, X., Wei, P., and Wang, Z. (2025). Recent advances in the genetics and innate immune cells of bullous pemphigoid. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1530407"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1111\/jdv.17253","article-title":"Clinical, biological and histological characteristics of bullous pemphigoid associated with anti-PD-1\/PD-L1 therapy: A national retrospective study","volume":"35","author":"Juzot","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/bjd.21836","article-title":"Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: A multicentre observational study","volume":"187","author":"Kawsar","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1001\/jamadermatol.2022.1624","article-title":"Association of Bullous Pemphigoid with Immune Checkpoint Inhibitor Therapy in Patients with Cancer: A Systematic Review","volume":"158","author":"Asdourian","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"adv00224","DOI":"10.2340\/00015555-3457","article-title":"A Systematic Review of Drug-Induced Pemphigoid","volume":"100","author":"Verheyden","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Moro, F., Fania, L., Sinagra, J.L.M., Salemme, A., and Di Zenzo, G. (2020). Bullous Pemphigoid: Trigger and Predisposing Factors. Biomolecules, 10.","DOI":"10.3390\/biom10101432"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5114","DOI":"10.1111\/bph.15233","article-title":"Identification of novel therapeutic targets for blocking acantholysis in pemphigus","volume":"177","author":"Burmester","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"102589","DOI":"10.1016\/j.coi.2025.102589","article-title":"Can we cure bullous skin diseases?","volume":"95","author":"Liu","year":"2025","journal-title":"Curr. Opin. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jaad.2015.03.016","article-title":"Coexistence of autoimmune bullous diseases (AIBDs) and psoriasis: A series of 145 cases","volume":"73","author":"Ohata","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s12026-018-9031-6","article-title":"The coexistence of pemphigus and psoriasis: A systematic review and meta-analysis","volume":"67","author":"Kridin","year":"2019","journal-title":"Immunol. Res."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Lee, A.Y., Kim, T., and Kim, J.H. (2023). Understanding CD4(+) T cells in autoimmune bullous diseases. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1161927"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jid.2021.04.040","article-title":"Pemphigus and Pemphigoid: From Disease Mechanisms to Druggable Pathways","volume":"142","author":"Ellebrecht","year":"2022","journal-title":"J. Investig. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/bjd\/ljae107","article-title":"Beyond the skin: B cells in pemphigus vulgaris, tolerance and treatment","volume":"191","author":"Strandmoe","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Egu, D.T., Schmitt, T., and Waschke, J. (2022). Mechanisms Causing Acantholysis in Pemphigus-Lessons from Human Skin. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.884067"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s10495-022-01726-z","article-title":"Apoptolysis: A less understood concept in the pathogenesis of Pemphigus Vulgaris","volume":"27","author":"Ramani","year":"2022","journal-title":"Apoptosis"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"8044","DOI":"10.1038\/s41467-024-51747-2","article-title":"Unbiased screening identifies regulators of cell-cell adhesion and treatment options in pemphigus","volume":"15","author":"Franz","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/bjd\/ljaf142","article-title":"Direct inhibition precedes p38 mitogen activated protein kinase-mediated uncoupling in desmosomes to reduce desmoglein 3 adhesion by pemphigus autoantibodies","volume":"193","author":"Fuchs","year":"2025","journal-title":"Br. J. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/1346-8138.70077","article-title":"Updates in Pathogenesis of Pemphigus Vulgaris","volume":"53","author":"Yang","year":"2026","journal-title":"J. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Huang, D., Zhang, Y., Kong, L., Lu, J., and Shi, Y. (2023). Janus kinase inhibitors in autoimmune bullous diseases. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1220887"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"102661","DOI":"10.1016\/j.autrev.2020.102661","article-title":"The role of T cells in pemphigus vulgaris and bullous pemphigoid","volume":"19","author":"Fang","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1111\/jdv.19239","article-title":"Interleukin-37 inhibits desmoglein-3 endocytosis and keratinocyte dissociation via upregulation of Caveolin-1 and inhibition of the STAT3 pathway","volume":"37","author":"Liang","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/postgradmedj-2015-133419","article-title":"TNF-alpha in a molecularly targeted therapy of psoriasis and psoriatic arthritis","volume":"92","author":"Mazurek","year":"2016","journal-title":"Postgrad. Med. J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/bjd.19679","article-title":"ST18 affects cell-cell adhesion in pemphigus vulgaris in a tumour necrosis factor-\u03b1-dependent fashion","volume":"184","author":"Assaf","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12967-022-03387-7","article-title":"Transcriptomic profiling of pemphigus lesion infiltrating mononuclear cells reveals a distinct local immune microenvironment and novel lncRNA regulators","volume":"20","author":"Huang","year":"2022","journal-title":"J. Transl. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e166357","DOI":"10.1172\/JCI166357","article-title":"Microenvironmental network of clonal CXCL13+CD4+ T cells and Tregs in pemphigus chronic blisters","volume":"133","author":"Han","year":"2023","journal-title":"J. Clin. Investig."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/bjd\/ljaf130","article-title":"Interleukin (IL)-34 promotes the inflammatory role of IL-1\u03b2-producing myeloid cells in pemphigus lesions","volume":"193","author":"Huang","year":"2025","journal-title":"Br. J. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/bjd\/ljaf458","article-title":"Role of protein kinase C subtype-specific signalling in regulating adhesion in human keratinocytes and skin in pemphigus","volume":"194","author":"Schmitt","year":"2026","journal-title":"Br. J. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jid.2025.05.008","article-title":"Single-Cell RNA Sequencing + TCR Sequencing Reveal the Proportion and Characteristics of Dual TCR T Cells in Tertiary Lymphoid Structures in Pemphigus","volume":"146","author":"Quan","year":"2026","journal-title":"J. Investig. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s12016-023-08973-1","article-title":"Advancing Treatment in Bullous Pemphigoid: A Comprehensive Review of Novel Therapeutic Targets and Approaches","volume":"65","author":"Chen","year":"2023","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Genovese, G., Di Zenzo, G., Cozzani, E., Berti, E., Cugno, M., and Marzano, A.V. (2019). New Insights Into the Pathogenesis of Bullous Pemphigoid: 2019 Update. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01506"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Yan, T., and Zhang, Z. (2023). Adaptive and innate immune pathogenesis of bullous pemphigoid: A review. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1144429"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Chiorean, R.M., Baican, A., Mustafa, M.B., Lischka, A., Leucuta, D.C., Feldrihan, V., Hertl, M., and Sitaru, C. (2018). Complement-Activating Capacity of Autoantibodies Correlates with Disease Activity in Bullous Pemphigoid Patients. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02687"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Karsten, C.M., Beckmann, T., Holtsche, M.M., Tillmann, J., Tofern, S., Schulze, F.S., Heppe, E.N., Ludwig, R.J., Zillikens, D., and K\u00f6nig, I.R. (2018). Tissue Destruction in Bullous Pemphigoid Can Be Complement Independent and May Be Mitigated by C5aR2. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.00488"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jaut.2016.06.019","article-title":"IgG4 autoantibodies are inhibitory in the autoimmune disease bullous pemphigoid","volume":"73","author":"Zuo","year":"2016","journal-title":"J. Autoimmun."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/1346-8138.16652","article-title":"Pruritogens in pemphigoid diseases: Possible therapeutic targets for a burdensome symptom","volume":"50","author":"Hiroyasu","year":"2023","journal-title":"J. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1046\/j.1523-1747.2003.12146.x","article-title":"Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid","volume":"120","author":"Dimson","year":"2003","journal-title":"J. Investig. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41598-017-00235-3","article-title":"Dysregulation of mCD46 and sCD46 contribute to the pathogenesis of bullous pemphigoid","volume":"7","author":"Qiao","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Hiroyasu, S., Turner, C.T., Richardson, K.C., and Granville, D.J. (2019). Proteases in Pemphigoid Diseases. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01454"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e21746","DOI":"10.1096\/fj.202100145R","article-title":"Neutrophil extracellular traps contribute to immune dysregulation in bullous pemphigoid via inducing B-cell differentiation and antibody production","volume":"35","author":"Fang","year":"2021","journal-title":"FASEB J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"9690","DOI":"10.1038\/s41598-018-28070-0","article-title":"Granzyme B is elevated in autoimmune blistering diseases and cleaves key anchoring proteins of the dermal-epidermal junction","volume":"8","author":"Russo","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.jid.2017.03.019","article-title":"TWEAK\/Fn14 Activation Contributes to the Pathogenesis of Bullous Pemphigoid","volume":"137","author":"Liu","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.jid.2017.09.037","article-title":"Semaphorin 4D from CD15(+) Granulocytes via ADAM10-Induced Cleavage Contributes to Antibody Production in Bullous Pemphigoid","volume":"138","author":"Shen","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.jaad.2024.08.033","article-title":"Efficacy and safety of low-dose interleukin 2 in the treatment of moderate-to-severe bullous pemphigoid: A single center perspective-controlled trial","volume":"91","author":"Xue","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Wang, Z., Lu, Y., Cui, H., Zhang, Y., Meng, L., Chang, W., Yang, X., and Ye, J. (2026). Regulatory T cells in bullous pemphigoid: Biological characteristics, dysfunction, and pathogenic roles. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1775932"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jid.2025.06.1583","article-title":"Autoreactive T Follicular Helper Cells Drive Induction of Bullous Pemphigoid-Like Skin Disease","volume":"146","author":"Ramcke","year":"2026","journal-title":"J. Investig. Dermatol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Ma, S., So, M., Ghelani, A., Srivas, R., Sahoo, A., Hall, R., Liu, W., Wu, H., Yu, S., and Lu, S. (2023). Attenuated IL-2 muteins leverage the TCR signal to enhance regulatory T cell homeostasis and response in vivo. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1257652"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"766","DOI":"10.2340\/00015555-2951","article-title":"Eosinophils are a Major Source of Interleukin-31 in Bullous Pemphigoid","volume":"98","author":"Rudrich","year":"2018","journal-title":"Acta Derm. Venereol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/08820139.2020.1832113","article-title":"Association between TH2 Cytokine Gene Polymorphisms and Risk of Bullous Pemphigoid","volume":"51","author":"Moravvej","year":"2022","journal-title":"Immunol. Investig."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaut.2018.09.003","article-title":"IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid","volume":"96","author":"Chakievska","year":"2019","journal-title":"J. Autoimmun."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaci.2016.08.012","article-title":"Bullous pemphigoid outcome is associated with CXCL10-induced matrix metalloproteinase 9 secretion from monocytes and neutrophils but not lymphocytes","volume":"139","author":"Riani","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Giusti, D., Bini, E., Terryn, C., Didier, K., Le Jan, S., Gatouillat, G., Durlach, A., Nesmond, S., Muller, C., and Bernard, P. (2019). NET Formation in Bullous Pemphigoid Patients with Relapse Is Modulated by IL-17 and IL-23 Interplay. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00701"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Le Jan, S., Muller, C., Plee, J., Durlach, A., Bernard, P., and Antonicelli, F. (2019). IL-23\/IL-17 Axis Activates IL-1beta-Associated Inflammasome in Macrophages and Generates an Auto-Inflammatory Response in a Subgroup of Patients with Bullous Pemphigoid. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01972"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Cole, C., Vinay, K., Borradori, L., and Amber, K.T. (2022). Insights Into the Pathogenesis of Bullous Pemphigoid: The Role of Complement-Independent Mechanisms. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.912876"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Lin, X., Li, X., Zhai, Z., and Zhang, M. (2025). JAK-STAT pathway, type I\/II cytokines, and new potential therapeutic strategy for autoimmune bullous diseases: Update on pemphigus vulgaris and bullous pemphigoid. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1563286"},{"key":"ref_73","first-page":"19","article-title":"JAK-inhibitors in dermatology\u2014Small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects","volume":"20","author":"Klein","year":"2022","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"6716419","DOI":"10.1155\/2017\/6716419","article-title":"Expression of the JAK\/STAT Signaling Pathway in Bullous Pemphigoid and Dermatitis Herpetiformis","volume":"2017","author":"Juczynska","year":"2017","journal-title":"Mediat. Inflamm."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/jdv.16780","article-title":"Expression of PD-1 and Tim-3 is increased in skin of patients with bullous pemphigoid and pemphigus vulgaris","volume":"35","author":"Ernst","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.jaad.2022.10.020","article-title":"Immune checkpoint inhibitor-induced bullous pemphigoid quandaries","volume":"87","author":"Heymann","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Guan, S., Zhang, L., Zhang, J., Song, W., and Zhong, D. (2023). A case report of steroid-refractory bullous pemphigoid induced by immune checkpoint inhibitor therapy. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1068978"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Mise, J., Jukic, I.L., and Marinovic, B. (2022). Rituximab\u2014Progress but Still Not a Final Resolution for Pemphigus Patients: Clinical Report From a Single Center Study. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.884931"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/bjd.18482","article-title":"Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect","volume":"182","author":"Chen","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_80","unstructured":"Food and Drug Administration (2018). FDA Approves Rituximab for Adult Patients with Moderate to Severe Pemphigus Vulgaris."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jaad.2025.05.1374","article-title":"Efficacy, safety, and B-cell depletion capacity of 3 rituximab dosing regimens in the treatment of moderate-to-severe pemphigus vulgaris and pemphigus foliaceus: A 52-week clinical trial","volume":"93","author":"Cao","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.jid.2021.09.013","article-title":"Temporal Outcomes after Rituximab Therapy for Pemphigus Vulgaris","volume":"142","author":"Tovanabutra","year":"2022","journal-title":"J. Investig. Dermatol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Liu, S.H., Wang, S.H., and Zuo, Y.G. (2025). Efficacy and safety of low dose rituximab in pemphigus: An updated systematic review and meta-analysis. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1605243"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamadermatol.2022.5182","article-title":"Association of Rituximab with Risk of Long-term Cardiovascular and Metabolic Outcomes in Patients with Pemphigus","volume":"159","author":"Kridin","year":"2023","journal-title":"JAMA Dermatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/bjd\/ljac118","article-title":"Risk of infections in patients with pemphigus treated with rituximab vs. azathioprine or mycophenolate mofetil: A large-scale global cohort study","volume":"188","author":"Kridin","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamadermatol.2024.6130","article-title":"Optimizing Pemphigus Management with Rituximab and Short-Term Relapse Predictors","volume":"161","author":"Hebert","year":"2025","journal-title":"JAMA Dermatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/bjd.13717","article-title":"Management of bullous pemphigoid: The European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology","volume":"172","author":"Feliciani","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Cao, P., Xu, W., and Zhang, L. (2022). Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.928621"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40257-023-00832-1","article-title":"Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update","volume":"25","author":"Karakioulaki","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.2165\/11203850-000000000-00000","article-title":"Ofatumumab","volume":"70","author":"Sanford","year":"2010","journal-title":"Drugs"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jdin.2025.05.018","article-title":"Ofatumumab for the management of refractory pemphigus vulgaris: A case series","volume":"22","author":"Sarsam","year":"2025","journal-title":"JAAD Int."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/17512433.2024.2350943","article-title":"What is novel in the clinical management of pemphigus vulgaris?","volume":"17","author":"Vafaeian","year":"2024","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"ref_93","first-page":"1338","article-title":"Successful Treatment of Pemphigus Vulgaris with Ofatumumab","volume":"17","author":"Rapp","year":"2018","journal-title":"J. Drugs Dermatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jdcr.2020.05.034","article-title":"Refractory pemphigus vulgaris successfully treated with ofatumumab","volume":"6","author":"Klufas","year":"2020","journal-title":"JAAD Case Rep."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/1346-8138.17108","article-title":"Ofatumumab subcutaneous injection successfully treated patients with pemphigus vulgaris relapse post rituximab","volume":"51","author":"Zhang","year":"2024","journal-title":"J. Dermatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.1111\/jdv.20245","article-title":"Evaluation of combination therapy with ofatumumab and systemic corticosteroids for pemphigus: A multi-centre cohort study","volume":"39","author":"Mao","year":"2025","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Zhang, X., Wang, Y., Tan, P., Zhou, X., Xiao, Y., Feng, X., Li, J., Wei, M., Zou, M., and Kim, G. (2025). The effectiveness and safety of ofatumumab for the treatment of pemphigus vulgaris: A cohort study based on a registry database. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1537334"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e16679","DOI":"10.1016\/j.heliyon.2023.e16679","article-title":"Targeting therapy in pemphigus: Where are we now and where are we going?","volume":"9","author":"Abulikemu","year":"2023","journal-title":"Heliyon"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1001\/jamadermatol.2014.1939","article-title":"Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris","volume":"150","author":"Ellebrecht","year":"2014","journal-title":"JAMA Dermatol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"102802","DOI":"10.1016\/j.msard.2021.102802","article-title":"Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis","volume":"49","author":"Capasso","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jdcr.2021.08.005","article-title":"Pemphigus vulgaris successfully treated with ocrelizumab following rituximab allergy","volume":"16","author":"Benesh","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_102","first-page":"e1104","article-title":"Ocrelizumab, an alternative to rituximab in refractory pemphigus vulgaris management","volume":"37","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_103","first-page":"e58834","article-title":"A Comprehensive Review on the Efficacy of Anti-CD20 Therapies in Pemphigus Treatment","volume":"16","author":"Khan","year":"2024","journal-title":"Cureus"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e15621","DOI":"10.1111\/dth.15621","article-title":"Belimumab for the treatment of pemphigus","volume":"35","author":"Ruan","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Hebert, V., Maho-Vaillant, M., Golinski, M.L., Petit, M., Riou, G., Boyer, O., Musette, P., Calbo, S., and Joly, P. (2021). Modifications of the BAFF\/BAFF-Receptor Axis in Patients with Pemphigus Treated with Rituximab Versus Standard Corticosteroid Regimen. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.666022"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Li, L., Shen, S., Shao, S., Dang, E., Wang, G., Fang, H., and Qiao, H. (2025). The role of B cell-activating factor system in autoimmune diseases: Mechanisms, disease implications, and therapeutic advances. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1538555"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4103\/ijd.ijd_599_24","article-title":"Pemphigus Vulgaris Successfully Treated with Belimumab: A Case Report","volume":"71","author":"Zheng","year":"2026","journal-title":"Indian J. Dermatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.jaad.2015.11.008","article-title":"Future therapies for pemphigus vulgaris: Rituximab and beyond","volume":"74","author":"Huang","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"103291","DOI":"10.1016\/j.jaut.2024.103291","article-title":"Telitacicept: A novel horizon in targeting autoimmunity and rheumatic diseases","volume":"148","author":"Zeng","year":"2024","journal-title":"J. Autoimmun."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/bjd\/ljaf023","article-title":"Exploring telitacicept in a patient with pemphigus vulgaris","volume":"192","author":"Zhang","year":"2025","journal-title":"Br. J. Dermatol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"501263","DOI":"10.1016\/j.abd.2025.501263","article-title":"BLyS\/APRIL dual inhibition by telitacicept for refractory pemphigus vulgaris combined with hepatocellular cancer","volume":"101","author":"Chen","year":"2026","journal-title":"An. Bras. Dermatol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/ijd.70166","article-title":"Successful Treatment of Refractory Severe Pemphigus with Telitacicept as Adjunctive Therapy: Two Case Reports","volume":"65","author":"Jiang","year":"2026","journal-title":"Int. J. Dermatol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1684\/ejd.2025.4997","article-title":"Telitacicept in combination with systemic steroid therapy in a patient with refractory pemphigus vulgaris and tuberculosis: A case report","volume":"35","author":"Zhang","year":"2025","journal-title":"Eur. J. Dermatol."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Zakrzewicz, A., Vanderheyden, K., Galaly, Y., Feldhoff, S., Sips, M., Brinkhaus, M., and Tikkanen, R. (2024). Binding to the neonatal Fc receptor enhances the pathogenicity of anti-desmoglein-3 antibodies in keratinocytes. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1473637"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jdcr.2025.04.012","article-title":"Treatment of refractory pemphigus vulgaris with efgartigimod","volume":"61","author":"Helm","year":"2025","journal-title":"JAAD Case Rep."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bjd.20782","article-title":"Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: A phase II multicentre, open-label feasibility trial","volume":"186","author":"Goebeler","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Maho-Vaillant, M., Sips, M., Golinski, M.L., Vidarsson, G., Goebeler, M., Stoevesandt, J., Bata-Cs\u00f6rg\u0151, Z., Balbino, B., Verheesen, P., and Joly, P. (2022). FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus Foliaceus. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.863095"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Zakrzewicz, A., W\u00fcrth, C., Beckert, B., Feldhoff, S., Vanderheyden, K., Foss, S., Andersen, J.T., Haard, H., Verheesen, P., and Bobkov, V. (2022). Stabilization of Keratinocyte Monolayer Integrity in the Presence of Anti-Desmoglein-3 Antibodies through FcRn Blockade with Efgartigimod: Novel Treatment Paradigm for Pemphigus?. Cells, 11, Erratum in Cells\u00a02022, 11, 1700.","DOI":"10.3390\/cells11101700"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jid.2025.09.373","article-title":"Boom or Bust: Clinical Trials in Pemphigus and Other B-Cell-Mediated Autoimmune Diseases","volume":"146","author":"Rujitharanawong","year":"2026","journal-title":"J. Investig. Dermatol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40265-026-02292-3","article-title":"Autoimmune Bullous Diseases: Therapeutic Update","volume":"86","author":"Kasperkiewicz","year":"2026","journal-title":"Drugs"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/path.6220","article-title":"Bullous pemphigoid induced by IgG targeting type XVII collagen non-NC16A\/NC15A extracellular domains is driven by Fc gamma receptor- and complement-mediated effector mechanisms and is ameliorated by neonatal Fc receptor blockade","volume":"262","author":"Pigors","year":"2024","journal-title":"J. Pathol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1016\/j.jid.2024.05.013","article-title":"Neonatal Fc Receptor Inhibition Reduces Bullous Pemphigoid Anti-Basement Membrane Zone IgG Deposition and Blistering in 3-Dimensional Human Skin Equivalents","volume":"144","author":"Bao","year":"2024","journal-title":"J. Investig. Dermatol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa2028564","article-title":"Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris","volume":"384","author":"Werth","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1001\/jamadermatol.2023.5679","article-title":"Sustained Remission Without Corticosteroids Among Patients with Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 Trial","volume":"160","author":"Tedbirt","year":"2024","journal-title":"JAMA Dermatol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): A prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa067752","article-title":"A single cycle of rituximab for the treatment of severe pemphigus","volume":"357","author":"Joly","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Jafari, S.M.A., Feldmeyer, L., Bossart, S., Simon, D., Schlapbach, C., and Borradori, L. (2020). Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.611549"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Tigges, M., Drager, S., Piccini, I., Bieber, K., Vorobyev, A., Edelkamp, J., Bertolini, M., and Ludwig, R.J. (2025). Pemphigoid disease model systems for clinical translation. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1537428"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Xu, Q., Chen, L., Chen, J., Zhang, J., Zou, Y., Gong, T., and Ji, C. (2021). Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.738907"},{"key":"ref_130","unstructured":"Food and Drug Administration (2025). FDA Approves Dupilumab for Adult Patients with Bullous Pemphigoid."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamadermatol.2023.2428","article-title":"Evaluation of Dupilumab in Patients with Bullous Pemphigoid","volume":"159","author":"Zhao","year":"2023","journal-title":"JAMA Dermatol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jdin.2025.10.004","article-title":"Dupilumab for bullous pemphigoid: Umbrella review of systematic reviews and meta-analyses","volume":"24","author":"Thapa","year":"2026","journal-title":"JAAD Int."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1007\/s12325-024-02810-3","article-title":"Study Design of a Phase 2\/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT","volume":"41","author":"Murrell","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Wang, S.H., Shan, Y., Li, S.Z., and Zuo, Y.G. (2023). Anti-interleukin 4 receptor alpha antibody for the treatment of Chinese bullous pemphigoid patients with diverse comorbidities and a 1-year follow-up: A monocentric real-world study. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1165106"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/bjd\/ljae403","article-title":"Real-world evaluation of the effectiveness and safety of dupilumab in bullous pemphigoid: An ambispective multicentre case series","volume":"192","author":"Guerrero","year":"2025","journal-title":"Br. J. Dermatol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"13030\/qt25q9w6r9","DOI":"10.5070\/D32511046147","article-title":"Dupilumab for bullous pemphigoid with intractable pruritus","volume":"25","author":"Seidman","year":"2019","journal-title":"Dermatol. Online J."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.jaad.2025.01.086","article-title":"Bullous pemphigoid: A practical approach to diagnosis and management in the modern era","volume":"92","author":"Powers","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_138","first-page":"596205","article-title":"Corticosteroid-Sparing Control of Bullous Pemphigoid with Dupilumab and Tripterygium Glycosides: A Real-World Cohort with Longitudinal Transcriptomics","volume":"19","author":"Wang","year":"2026","journal-title":"J. Inflamm. Res."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Chen, S., Zhan, S., Hua, C., Tang, Y., and Cheng, H. (2022). A Novel Combined Use of Dupilumab for Treatment of Aggressive Refractory Pemphigus Vulgaris Complicated with Pulmonary Tuberculosis: A Case Report and the RNA-seq Analysis. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.825796"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/bjd\/ljad369","article-title":"Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: A French national multicentre retrospective study of 100 patients","volume":"190","author":"Chebani","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Alexandre, M., Bohelay, G., Gille, T., Le Roux-Villet, C., Soued, I., Morin, F., Caux, F., Grootenboer-Mignot, S., and Prost-Squarcioni, C. (2022). Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.874108"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.annonc.2021.02.016","article-title":"IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies","volume":"32","author":"Barrios","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/bjd\/ljad432","article-title":"Omalizumab therapy of bullous pemphigoid","volume":"190","author":"Fairley","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jaci.2008.11.035","article-title":"Pathogenicity of IgE in autoimmunity: Successful treatment of bullous pemphigoid with omalizumab","volume":"123","author":"Fairley","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"110721","DOI":"10.1016\/j.isci.2024.110721","article-title":"Stapokibart (CM310) targets IL-4R\u03b1 for the treatment of type 2 inflammation","volume":"27","author":"Liu","year":"2024","journal-title":"iScience"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1111\/all.16368","article-title":"Long-term efficacy and safety of stapokibart for moderate-to-severe atopic dermatitis: 52-week results from a phase 3 trial","volume":"80","author":"Zhao","year":"2025","journal-title":"Allergy"},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Wang, S.H., Liu, S.H., Zhang, J., Zhang, H., Wang, Y., Li, S.Z., and Zuo, Y.G. (2026). Real-World Outcomes of Stapokibart-Based Combination Therapy for Bullous Pemphigoid: A Single-Center Retrospective Cohort. Clin. Exp. Dermatol., llag269.","DOI":"10.1093\/ced\/llag269"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Du, N., Wang, Y., Yang, J., Lv, X., and Min, W. (2026). Stapokibart\u2019s clinical effectiveness in treating moderate-to-severe bullous pemphigoid in the elderly. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1689991"},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Yu, M., Tian, S., and Meng, F. (2026). Successful management of DPP-4 inhibitor-induced bullous pemphigoid with Stapokibart injection in an elderly diabetic patient: A case report. Front. Med., 13.","DOI":"10.3389\/fmed.2026.1755336"},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Zhou, T., Peng, B., and Geng, S. (2021). Emerging Biomarkers and Therapeutic Strategies for Refractory Bullous Pemphigoid. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.718073"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1001\/jamadermatol.2022.1156","article-title":"Evaluation of Nomacopan for Treatment of Bullous Pemphigoid: A Phase 2a Nonrandomized Controlled Trial","volume":"158","author":"Sadik","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/1346-8138.17742","article-title":"Effectiveness of Dupilumab and Omalizumab in Bullous Pemphigoid: A Nationwide Retrospective Cohort Study","volume":"52","author":"Avallone","year":"2025","journal-title":"J. Dermatol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/bjd\/ljaf219","article-title":"Janus kinase\/signal transducer and activator of transcription signalling pathway is involved in the immune mechanism of bullous pemphigoid","volume":"193","author":"Chung","year":"2025","journal-title":"Br. J. Dermatol."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Li, X., Zhang, L., Gu, H., He, W., Zhai, Z., and Zhang, M. (2024). Treatment and molecular analysis of bullous pemphigoid with tofacitinib: A case report and review of current literature. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1464474"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"110591","DOI":"10.1016\/j.intimp.2023.110591","article-title":"Concurrent bullous pemphigoid and psoriasis vulgaris successfully treated with Janus kinase inhibitor tofacitinib: A case report and review of the literature","volume":"122","author":"Li","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Patsatsi, A., and Murrell, D.F. (2021). Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus. Front. Med., 8.","DOI":"10.3389\/fmed.2021.708071"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/jdv.18318","article-title":"Phase 2 BELIEVE study part B: Efficacy and safety of rilzabrutinib for patients with pemphigus vulgaris","volume":"36","author":"Murrell","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s42358-024-00401-y","article-title":"Targeting Bruton\u2019s tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: From molecular mechanisms to leading treatments","volume":"64","author":"Tavakoli","year":"2024","journal-title":"Adv. Rheumatol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.jid.2024.02.023","article-title":"Efficacy and Safety of Rilzabrutinib in Pemphigus: PEGASUS Phase 3 Randomized Study","volume":"144","author":"Murrell","year":"2024","journal-title":"J. Investig. Dermatol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41467-022-35741-0","article-title":"Apremilast prevents blistering in human epidermis and stabilizes keratinocyte adhesion in pemphigus","volume":"14","author":"Sigmund","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Meier, K., Holstein, J., Solimani, F., Waschke, J., and Ghoreschi, K. (2020). Case Report: Apremilast for Therapy-Resistant Pemphigus Vulgaris. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.588315"},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Delvaux, C., Bohelay, G., Sitbon, I.Y., Soued, I., Alexandre, M., Cucherousset, J., Gilardin, L., Diep, A., Caux, F., and Le Roux-Villet, C. (2024). Activity of apremilast in a patient with severe pemphigus vulgaris: Case report. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1404185"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1007\/s10787-025-01778-y","article-title":"PDE4 inhibitors in psoriasis therapy: Current insights and future directions","volume":"33","author":"Sharma","year":"2025","journal-title":"Inflammopharmacology"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"e187481","DOI":"10.1172\/jci.insight.187481","article-title":"Epac1 contributes to apremilast-mediated rescue of pemphigus autoantibody-induced loss of keratinocyte adhesion","volume":"10","author":"Sigmund","year":"2025","journal-title":"JCI Insight"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1111\/ajd.14312","article-title":"Ineffectiveness of apremilast in moderate-to-severe pemphigus: A case series of three patients","volume":"65","author":"Zhang","year":"2024","journal-title":"Australas. J. Dermatol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.jid.2024.01.009","article-title":"The Syk Inhibitor Entospletinib Abolishes Dermal-Epidermal Separation in a Fully Human Ex Vivo Model of Bullous Pemphigoid","volume":"144","author":"Vikar","year":"2024","journal-title":"J. Investig. Dermatol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/14728214.2025.2555080","article-title":"Emerging drugs for the treatment of bullous pemphigoid: What\u2019s new on the horizon?","volume":"30","author":"Olbrich","year":"2025","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/bjd\/ljac078","article-title":"Tofacitinib in recalcitrant bullous pemphigoid: A report of seven cases","volume":"188","author":"Fan","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.2147\/CCID.S536993","article-title":"Tofacitinib as a Novel Therapeutic Option for Pemphigus Vulgaris: A Case Report and Mechanistic Insights","volume":"18","author":"Li","year":"2025","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/ijd.17464","article-title":"Upadacitinib leading to resolution of refractory mucosal erosions in a case of pemphigus vulgaris","volume":"64","author":"Hren","year":"2025","journal-title":"Int. J. Dermatol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.jaci.2026.04.021","article-title":"IFN-\u03b3-driven CD8+ T-cell-keratinocyte cross talk underlies inflammation and blistering in pemphigus lesions","volume":"158","author":"Shen","year":"2026","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1172\/JCI138416","article-title":"Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris","volume":"130","author":"Lee","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Zhang, A., Yang, Z., Huang, T., and Wang, M. (2024). Causal association between psoriasis vulgaris and bullous pemphigoid: A two-sample bidirectional Mendelian randomization study. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1365118"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.abd.2023.07.017","article-title":"Multirefractory bullous pemphigoid, psoriasis and psoriatic arthritis successfully treated with guselkumab","volume":"99","year":"2024","journal-title":"An. Bras. Dermatol."},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Drenovska, K., Valeva, E., Shahid, M., and Vassileva, S. (2023). Case Report: Coexistence of bullous pemphigoid and psoriasis: Therapeutic challenge and IL17A-targeted parallel treatment strategy. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1148660"},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Li, L., Liu, J., Lu, J., Wu, J., Zhang, X., Ma, T., Wu, X., Zhu, Q., Chen, Z., and Tai, Z. (2025). Interventions in cytokine signaling: Novel horizons for psoriasis treatment. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1573905"},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Hong, J.J., Hadeler, E.K., Mosca, M.L., Brownstone, N.D., Bhutani, T., and Liao, W.J. (2021). Off-label uses of TNFa inhibitors and IL12\/23 inhibitors in dermatology. Dermatol. Online J., 27.","DOI":"10.5070\/D3271156085"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1365-2133.2005.06744.x","article-title":"Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab","volume":"153","author":"Jacobi","year":"2005","journal-title":"Br. J. Dermatol."},{"key":"ref_180","first-page":"940","article-title":"Successful treatment of pemphigus vulgaris with etanercept in four patients","volume":"8","author":"Shetty","year":"2009","journal-title":"J. Drugs Dermatol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1001\/archdermatol.2010.409","article-title":"A pilot study of etanercept treatment for pemphigus vulgaris","volume":"147","author":"Fiorentino","year":"2011","journal-title":"Arch. Dermatol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1365-2133.2005.06672.x","article-title":"Infliximab in the management of severe pemphigus vulgaris","volume":"153","author":"Pardo","year":"2005","journal-title":"Br. J. Dermatol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1365-2133.2009.09208.x","article-title":"The use of sulfasalazine and pentoxifylline (low-cost antitumour necrosis factor drugs) as adjuvant therapy for the treatment of pemphigus vulgaris: A comparative study","volume":"161","author":"Marzouk","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s40257-022-00719-7","article-title":"Management of Coexisting Bullous Pemphigoid and Psoriasis: A Review","volume":"23","author":"Hsieh","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s00384-014-1924-9","article-title":"Bullous pemphigoid occurring under anti-tumor necrosis factor-\u03b1 therapy","volume":"29","author":"Rcci","year":"2014","journal-title":"Int. J. Colorectal Dis."},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Zhang, Y., and Jiang, G. (2024). Application of JAK inhibitors in paradoxical reaction through immune-related dermatoses. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1341632"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jamadermatol.2023.0549","article-title":"Paradoxical Psoriasiform Eruptions in Children Receiving Tumor Necrosis Factor alpha Inhibitors","volume":"159","author":"Eickstaedt","year":"2023","journal-title":"JAMA Dermatol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/j.jaad.2011.05.029","article-title":"Infliximab therapy failure in two patients with pemphigus vulgaris","volume":"67","author":"Iranzo","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10787-025-02079-0","article-title":"A systematic review of therapeutic and paradoxical roles of tumor necrosis factor \u03b1 inhibitors in autoimmune blistering diseases","volume":"34","author":"Ghane","year":"2026","journal-title":"Inflammopharmacology"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1097\/CM9.0000000000001510","article-title":"Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: A real-life cohort study","volume":"134","author":"Zhao","year":"2021","journal-title":"Chin. Med. J."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/bjd.19262","article-title":"Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study","volume":"184","author":"Reich","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1097\/CM9.0000000000001163","article-title":"Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis","volume":"133","author":"Cai","year":"2020","journal-title":"Chin. Med. J."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1111\/1346-8138.13909","article-title":"Development of bullous pemphigoid during secukinumab treatment for psoriasis","volume":"44","author":"Ho","year":"2017","journal-title":"J. Dermatol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1080\/09546634.2022.2089331","article-title":"Bullous pemphigoid induced by biologic drugs in psoriasis: A systematic review","volume":"33","author":"Steinhoff","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1111\/ijd.17778","article-title":"Dual Immune-Related Toxicities: Secukinumab-Induced Bullous Pemphigoid Following ICI-Associated Psoriasis in a Cancer Patient","volume":"64","author":"Paschou","year":"2025","journal-title":"Int. J. Dermatol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/1346-8138.16765","article-title":"Two cases with bullous pemphigoid relapsed after using interleukin-17A inhibitors for psoriasis: A paradoxical reaction","volume":"50","author":"Wang","year":"2023","journal-title":"J. Dermatol."},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Hu, F., Peng, H., Gong, J., Tao, X., Wang, X., Bao, J., He, P., Dirwanto, L., Liu, M., and Yang, H. (2025). Induced pemphigus erythematosus after treatment for plaque psoriasis with secukinumab: A case report. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1612422"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1111\/1346-8138.14760","article-title":"Secukinumab decreased circulating anti-BP180-NC16a autoantibodies in a patient with coexisting psoriasis vulgaris and bullous pemphigoid","volume":"46","author":"Kamata","year":"2019","journal-title":"J. Dermatol."},{"key":"ref_199","first-page":"1478","article-title":"Adjuvant treatment with secukinumab induced long term remission in a patient with severe bullous pemphigoid","volume":"18","author":"Holtsche","year":"2020","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1111\/ajd.13803","article-title":"Successful secukinumab treatment of active bullous pemphigoid and chronic severe psoriasis: A case report","volume":"63","author":"Yun","year":"2022","journal-title":"Australas. J. Dermatol."},{"key":"ref_201","doi-asserted-by":"crossref","unstructured":"Cao, S., Yang, B., Liu, Y., Liu, H., and Zhang, F. (2025). Combined biological therapy with dupilumab and secukinumab for coexisting bullous pemphigoid and psoriasis. Indian J. Dermatol. Venereol. Leprol., 1\u20133.","DOI":"10.25259\/IJDVL_1291_2024"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1111\/1346-8138.16189","article-title":"Incidental amelioration of bullous pemphigoid during ixekizumab treatment for psoriasis","volume":"49","author":"Lu","year":"2022","journal-title":"J. Dermatol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1111\/1346-8138.16559","article-title":"Ixekizumab successfully treated refractory psoriasis concurrent bullous pemphigoid","volume":"50","author":"Xiao","year":"2023","journal-title":"J. Dermatol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/bjd\/ljaf354","article-title":"Ustekinumab as a potential therapeutic agent in Bullous Pemphigoid: A biological and clinical proof-of-concept study","volume":"193","author":"Koliadenko","year":"2025","journal-title":"Br. J. Dermatol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40257-021-00603-w","article-title":"Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review","volume":"22","author":"Thatiparthi","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1111\/jdv.14002","article-title":"A successful treatment with ustekinumab in a case of relapsing bullous pemphigoid associated with psoriasis","volume":"31","author":"Loget","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1111\/bjd.12163","article-title":"A successful treatment with ustekinumab in a case of antilaminin-\u03b31 pemphigoid associated with psoriasis","volume":"168","author":"Majima","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/1346-8138.12943","article-title":"Development of bullous pemphigoid during treatment of psoriatic onycho-pachydermo periostitis with ustekinumab","volume":"42","author":"Nakayama","year":"2015","journal-title":"J. Dermatol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/ddg.14199","article-title":"Bullous pemphigoid without detection of autoantibodies in a patient with psoriasis under ustekinumab","volume":"19","author":"Querol","year":"2020","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_210","doi-asserted-by":"crossref","unstructured":"Kong, L., Huang, D., Lu, J., Zhang, Y., Li, Y., Yi, X., and Shi, Y. (2023). Development of bullous pemphigoid during treatment of psoriasis with ustekinumab: A case report and literature review. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1171802"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/jdv.19296","article-title":"Effectiveness, safety and quality-of-life effects of guselkumab and ustekinumab in patients with psoriasis: Week 104 results from the non-interventional, prospective, German multicentre PERSIST study","volume":"39","author":"Gerdes","year":"2025","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_212","first-page":"713","article-title":"Successful treatment with guselkumab of anti-p200 pemphigoid associated with plaque psoriasis","volume":"22","author":"Kitayama","year":"2024","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"e15207","DOI":"10.1111\/dth.15207","article-title":"Guselkumab-associated bullous pemphigoid in a psoriasis patient: A case report and review of the literature","volume":"35","author":"Burlando","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_214","doi-asserted-by":"crossref","unstructured":"Xi, R., Cao, Y., Zhuang, Q., Ma, L., Tao, M., and Li, Y. (2025). Bullous pemphigoid induced by anti-IL-23 monoclonal antibody in a psoriatic patient: A case report. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1709423"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/bjd.13350","article-title":"A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone","volume":"172","author":"Hall","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"2366535","DOI":"10.1080\/09546634.2024.2366535","article-title":"A case report of bullous pemphigoid following secukinumab therapy for a patient with psoriasis","volume":"35","author":"Wang","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.1097\/MJT.0000000000001642","article-title":"Secukinumab-Induced Bullous Pemphigoid in a Patient with Psoriatic Arthritis","volume":"31","author":"Fatima","year":"2024","journal-title":"Am. J. Ther."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"606758","DOI":"10.2147\/CCID.S606758","article-title":"Bullous Pemphigoid Possibly Induced by Deucravacitinib in a Patient with Psoriasis","volume":"19","author":"Lu","year":"2026","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1111\/1346-8138.16711","article-title":"A case of bullous pemphigoid developing after ixekizumab therapy for pityriasis rubra pilaris","volume":"50","author":"Sugihara","year":"2023","journal-title":"J. Dermatol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/ijd.14686","article-title":"Autoimmune blistering diseases provoked during the treatment of chronic inflammatory disease with biologic agents: A systematic review","volume":"59","author":"Gibson","year":"2020","journal-title":"Int. J. Dermatol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jaad.2020.12.010","article-title":"Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis","volume":"86","author":"Murphy","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_222","doi-asserted-by":"crossref","unstructured":"Zhang, J., Wang, S.H., and Zuo, Y.G. (2023). Paradoxical phenomena of bullous pemphigoid induced and treated by identical biologics. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1050373"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/19\/8779\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:18:30Z","timestamp":1791951510000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/19\/8779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":222,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["ijms27198779"],"URL":"https:\/\/doi.org\/10.3390\/ijms27198779","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]}}}